CStone Pharmaceuticals announced the CS1002 (anti-CTLA-4 monoclonal antibody) and CS1003 (anti-PD-1 monoclonal antibody) phase Ib study data in patients with advanced solid tumors at the 2021 ESMO annual meeting

Suzhou, China, September 19, 2021/PRNewswire/ - CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a leading biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapies and precision therapeutic drugs, At the 2021 European Society of Medical Oncology (ESMO) annual meeting, a phase Ib study of CS1002 (anti-CTLA-4 monoclonal antibody) and CS1003 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors was announced (CS1002- 101, NCT03523819) preliminary results (Poster ID: 981P)

The CS1002-101 study is a multi-center, open-label, dose-escalation and dose-expansion phase Ia/Ib study, which aims to evaluate the clinical safety of CS1002 monotherapy (phase Ia) and combination therapy with CS1003 (phase Ib) , Tolerance, pharmacokinetic characteristics and preliminary anti-tumor activity

In the phase Ib dose escalation part, the combination of four different dosing regimens of CS1002 and CS1003 was explored in patients with advanced solid tumors.

In the phase Ib dose expansion part, CS1003 (200mg fixed dose, 200mg fixed dose, Q3W) The effectiveness and safety of CS1002 in combination with two dose levels, namely the regular dose of CS1002 (1 mg/kg Q3W, up to 4 doses, group A), and the lower dose of CS1002 (0.

As of March 1, 2021, of the 16 evaluable MSI-H/dMMR solid tumor patients in groups A and B, the overall objective response rate (ORR) was 50%

A total of 33 patients participated in the safety analysis, and 29 patients (87.

Therefore, the combination therapy of anti-CTLA-4 mAb CS1002 and anti-PD-1 mAb CS1003 showed excellent and sustainable initial anti-tumor activity in the above two tumor types, regardless of the dose level of CS1002

Dr.

About CS1002 (anti-CTLA-4 monoclonal antibody)

CS1002 is an anti-CTLA-4 monoclonal antibody developed by CStone Pharmaceuticals

About CS1003 (anti-PD-1 monoclonal antibody)

CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1), which is being developed for immunotherapy of a variety of tumors

About CStone Pharmaceuticals

CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616) is a biopharmaceutical company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the ardent medical needs of cancer patients in China and around the world

For more information, please visit

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article

Source: CStone Pharmaceuticals